

Arrivo BioVentures' SIRT6 Activator Receives United States Adopted Name "Forvisirvat"

Forvisirvat is the first SIRT6-targeting therapy to receive a USAN and is the most advanced SIRT6 activator in human trials

MORRISVILLE, N.C., February 26, 2025—[Arrivo BioVentures](#) today announced that its late-stage Major Depressive Disorder (MDD) treatment, SP-624, has been officially assigned the United States Adopted Name (USAN) "Forvisirvat." Forvisirvat is a first-in-class activator of SIRT6, an enzyme involved in key biological processes such as DNA repair, mitochondrial function, inflammation, and glucose homeostasis, each of which is involved in depression.

"Forvisirvat represents an industry-first step forward to treating Major Depressive Disorder," said Arrivo CEO Steve Butts. "As a SIRT6 activator, Forvisirvat's epigenetic mechanism-of-action sets it apart from traditional antidepressants. Early data are encouraging, particularly in females with depression, underscoring its potential to address a critical gap in depression treatment."

Forvisirvat is the first SIRT6-targeting therapy to receive a USAN designation. The "sirvat" stem in its name denotes its classification within the sirtuin family, a new class of medications. Preclinical and clinical studies have demonstrated Forvisirvat's ability to enhance neural activity associated with mood regulation and cognition, supporting its development for MDD and potential expansion into cognitive disorders.

Currently, Forvisirvat is being evaluated in a large Phase 2b/3 clinical trial for MDD, following promising [Phase 2 results](#) that highlighted its efficacy in female patients.

About Arrivo BioVentures

Arrivo is developing first-of-its-kind medicines that target the root cause of hard-to-treat diseases with the goal of achieving meaningful outcomes for patients, allowing them to live longer, healthier lives. Arrivo has two clinical-stage pipeline candidates, Forvisirvat (SP-624) for major depressive disorder and RAB1-767 for predicted severe acute pancreatitis. Arrivo is based in Morrisville, N.C., on the edge of Research Triangle Park. For more information, visit www.arrivobio.com.

Media Contact:

Alexis Feinberg

Vice President, ICR Healthcare

Alexis.feinberg@icrhealthcare.com